INMB Q4 2018 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena

INMBINmune Bio, Inc.

$37M

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$2M

Net Income

-$2M

EPS (Diluted)

$-0.17

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$462,377

Free Cash Flow

-$462,377

Stock-Based Comp.

$954,817

Balance Sheet

Total Assets

$17M

Total Liabilities

$823,766

Stockholders' Equity

$17M

Cash & Equivalents

$186,204

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$2M	-$428,000	-339.3%
Net Income	-$2M	-$428,000	-339.3%